An international analysis published in Circulation and a new scientific statement from the American Heart Association both explore the latest data on heart complications associated with COVID-19. 

“If you were a patient of Dr. Verga’s, your heart was in brilliant hands,” according to one loving tribute. The 45-year-old cardiologist had been missing since March 20. 

Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.

Drug-coated balloons were associated with a lower risk of bleeding after PCI than drug-eluting stents, the study's authors reported. 

Adam Greenbaum, MD, co-director of the Structural Heart and Valve Center at Emory University Hospital Midtown in Atlanta, explains details from the late-breaking CLASP TR trial at ACC.22.

The new algorithm was designed to evaluate a user's heart rhythm while they are still or even sleeping. 

Did SAVR outcomes suffer due to the rapid rise of TAVR? A team of researchers aimed to find out with a brand new analysis. 

The noncancerous imaging features obtained before radiation therapy could be used in the future to help guide treatment decisions for these patients, experts suggested.